Last edition
News about "Medicinal Products for Human Use"
EMA Panel Backs Norgine?s XOLREMDI for WHIM Syndrome Under Exceptional Circumstances
The EMA’s CHMP recommends marketing authorisation for XOLREMDI (mavorixafor) to treat WHIM syndrome patients aged 12 and above, marking a major step toward the first licensed therapy for the rare disorder.
Medicinal Products For Human Use | 03/03/2026 | By News Bureau | 103
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members